Lisinopril and Carvedilol Reduce Cardiotoxicity in HER2+ Breast Cancer

10:53 EDT 13 Mar 2018 | Cancer Networks

Lisinopril and carvedilol reduced cardiotoxicity in patients with HER2-positive breast cancer treated with trastuzumab and anthracyclines.

Original Article: Lisinopril and Carvedilol Reduce Cardiotoxicity in HER2+ Breast Cancer

NEXT ARTICLE

More From BioPortfolio on "Lisinopril and Carvedilol Reduce Cardiotoxicity in HER2+ Breast Cancer"